Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Neoantigen Targeted Therapies Market?

The market size for neoantigen targeted therapies has seen a significant growth in the past few years. It is projected to increase from $3.4 billion in 2024 to $4.71 billion in 2025, growing at a compound annual growth rate (CAGR) of 38.3%. The historical growth of the market owes to progress in genomic sequencing, the development of immunotherapy, understanding of tumor immunology, the clinical success of checkpoint inhibitors, and improvements in molecular profiling.

The size of the market for neoantigen targeted therapies is anticipated to expand significantly in the forthcoming years. The market is projected to swell to a value of $15.93 billion in 2029, with a compound annual growth rate (CAGR) of 35.7%. The predicted growth during this period can be ascribed to progress in bioinformatics, the broadening of precision medicine, advancement in neoantigen vaccines, strategic therapeutic combinations, and biomarker validation. During the forecast period, prevalent trends include management of neoantigen resistance, therapies involving neoantigen-primed adoptive cells, combinatorial therapies based on neoantigen, assimilation of real-world data, and enhanced predictive models.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

What Underlying Factors Are Supporting The Neoantigen Targeted Therapies Market Growth?

The neoantigen targeted therapies market is anticipated to flourish due to the rising number of cancer cases. The term “incidence of cancer” refers to the emergence of fresh cancer cases within a certain population bracket over a specified duration. These neoantigen-targeted therapies are typically employed conjointly to address various forms of cancer. The American Cancer Society (ACS), a voluntary health organization based in the U.S, noted that in 2022, there was a stark increase in new cancer cases with 1.9 million individuals affected, a clear upsurge from the preceding years. Moreover, the year 2022 also witnessed about 609,360 cancer-related deaths in the U.S, underlining the serious impact and harshness of this ailment on individuals and their loved ones. Consequently, the proliferating instances of cancer cases are fueling the expansion of the neoantigen targeted therapies market.

How Does The Neoantigen Targeted Therapies Market Differ By Segment?

The neoantigen targeted therapiesmarket covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies; Neoantigen-Targeted Therapies Combined With Chemotherapy; Neoantigen-Targeted Therapies Combined With Targeted Therapies

How Are Global Trends Impacting The Development Of The Neoantigen Targeted Therapies Market?

Key players in the neoantigen targeted therapies market are engaging in strategic alliances to personalize cancer treatments and address issues that hinder current immunotherapy options for solid tumors. These strategic alliances allow firms to utilize each other’s capabilities and resources to mutually benefit and succeed. An example of this occurred in January 2023 when BioNTech SE, a biotech company based in Germany, joined forces with the UK Government. The purpose of this alliance is to progress the development of personalized mRNA cancer immunotherapies. It aims to provide specialized treatments for as many as 10,000 patients by 2030 and encompasses several pivotal areas, including cancer immunotherapy development, infectious disease vaccine research, and the establishment of a research and development hub in Cambridge. This initiative is expected to tap into the UK’s clinical trial structure and health data sets to enhance patient enrollment and choose appropriate sites for BioNTech’s mRNA treatments. The first clinical trials from the company in the UK are planned for later this year. These trials will focus on cancer vaccines that may potentially be incorporated into standard treatment regimens if they demonstrate efficacy.

Who Are The Global Leaders Steering The Neoantigen Targeted Therapies Market Forward?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Neoantigen Targeted Therapies Market?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Browse Through More Reports Similar to the Global Neoantigen Targeted Therapies Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model